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Summary The effects of tamoxifen, three of its in vivo metabolites and 3-hydroxytamoxifen on cellular
proliferation and the induction of four oestrogen-regulated RNAs (pNR-1, pNR-2, pNR-25 and cathepsin D)
have been measured in MCF-7 breast cancer cells in phenol red-free culture medium. Tamoxifen and 3-
hydroxytamoxifen acted as partial oestrogens to stimulate cell growth and the levels of the pNR-2 and pNR-
25 RNAs. They were full oestrogens for the induction of cathepsin D RNA and induced the pNR-l RNA
above the level found in oestrogen-treated cells. N-Desmethyltamoxifen and 4-hydroxytamoxifen behaved
like tamoxifen except that N-desmethyltamoxifen did not induce the pNR-2 RNA and was only a partial
oestrogen for the induction of cathepsin D RNA, and 4-hydroxytamoxifen did not induce the pNR-2 or
pNR-25 RNAs. In the presence of oestradiol, the four anti-oestrogens prevented the stimulation of growth
and reduced (pNR-2 and pNR-25) or increased (pNR-1) the RNA levels to those present in MCF-7 cells
treated with the anti-oestrogen alone. In contrast, for cathepsin D RNA levels there was a synergistic effect of
the anti-oestrogens and oestradiol. The concentration at which each anti-oestrogen was effective was related
to its affinity for the oestrogen receptor. Metabolite E was a full oestrogen for the induction of cell
proliferation and the oestrogen-regulated RNAs. pNR-25 and pNR-2 RNA levels correlated most closely with
effects on cell proliferation. These RNAs are therefore potentially the most useful for predicting the response
of breast cancer patients to tamoxifen therapy.
Breast cancer is a common disease that will often respond to
endocrine therapy. Tamoxifen is the most frequently used
endocrine therapy for post-menopausal women (Furr &
Jordan, 1984). Remission is obtained in a third of all
patients and in 50% of patients whose tumours contain
oestrogen receptors. However, many patients do not respond
and among those that do, the average time to relapse is only
14 months. Although tamoxifen is thought to act through
the oestrogen receptor, its mechanism of action is not fully
understood (Furr & Jordan, 1984).
Tamoxifen is extensively metabolised in vivo and it is
therefore important to understand the action of the
metabolites as well as that of the parent drug. In breast
cancer patients, N-desmethyltamoxifen and 4-hydroxy-
tamoxifen are the major metabolites found in plasma
and tumour cell extracts (Robinson & Jordan, 1988). Among
other minor metabolites found in patient plasma, metabolite
E is of note as it has been reported to be oestrogenic in rat
uterus and pituitary (Murphy et al., 1987; Robinson &
Jordan, 1988).
Several cell lines have been isolated from metastatic breast
cancer cells that express oestrogen receptor and whose
growth is stimulated by oestrogens (e.g. MCF-7: Soule et al.,
1973; Horwitz et al., 1978; Lippman et al., 1976). In previous
studies on the effects of tamoxifen and its metabolites on
growth (e.g. Coezy et al., 1982) cells were cultured in
medium containing the pH indicator dye phenol red, which
is a weak oestrogen (Berthois et al., 1986). Under these
conditions tamoxifen only inhibited cell growth. A
reappraisal of the effects of tamoxifen and its metabolites in
phenol red-free medium is therefore necessary, especially as
tamoxifen has been reported to stimulate the proliferation of
MCF-7 cells grown in phenol red-free medium (Berthois et
al., 1986).
A number of oestrogen-regulated RNAs have been
isolated recently from MCF-7 and ZR 75 cells (May &
Westley, 1986, 1988; Westley & May, 1987). The pNR-2
RNA corresponds to the pS2 RNA identified by others
(Masiakowski et al., 1982). It codes for a small cysteine rich
protein which is secreted by normal stomach mucosa (Rio et
al., 1988) and has structural similarities to IGF-1. It is
present in some breast tumours and appears to be regulated
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by oestrogen in the tumour cells (Rio et al., 1987). The
pNR-100 RNA codes for the lysosomal aspartyl protease
cathepsin D (Westley & May, 1987). The proteins encoded
by the pNR-1 and pNR-25 RNAs have not been identified
but the pNR-l RNA is of interest because it is induced by
tamoxifen and 4-hydroxytamoxifen (May & Westley, 1987).
In this study, the oestrogenic and antioestrogenic activities
of tamoxifen, N-desmethyltamoxifen, 4-hydroxytamoxifen, 3-
hydroxytamoxifen and metabolite E have been measured on
cell proliferation and on the induction of the oestrogen-
regulated pNR-1, pNR-2, pNR-25 and pNR-100 RNAs in
phenol red-free medium. The antioestrogens had widely
differing effects on cell proliferation; 4-hydroxytamoxifen
was the least oestrogenic while metabolite E was fully
oestrogenic.
Materials and methods
Cell culture
MCF-7 cells were maintained in Dulbecco's modified Eagle's
medium containing 10% foetal calf serum and insulin
(lggml-1). Charcoal-treated newborn calf serum was used
in all experiments designed to test the effects of oestrogens
and anti-oestrogens on cell growth or on the levels of the
oestrogen regulated RNAs. Newborn calf serum was used
because it contains lower concentrations of steroids than
fetal calf serum. This enables cells to be withdrawn more
effectively from the steroids present in normal growth
medium and facilitates the analysis of small agonist effects of
antioestrogens.
For analysis of RNA regulation, cells were grown in T25
flasks. They were then withdrawn from the steroids present
in the routine culture medium by culture for 7 days in
phenol red-free modified Eagle's medium containing 10%
newborn calf serum, treated with dextran-coated charcoal to
remove endogenous steroids, and insulin (1 Mgml-1). During
the first 3 days of culture the cells were washed twice before
the medium change. Withdrawn cells were then cultured
continuously in the above medium, whereas treated cells
were cultured in the above medium supplemented with the
indicated hormone. During withdrawal and treatment,
culture medium was changed daily. For measurement of cell
growth, cells were plated into 16-mm wells at approximately
10% confluence and allowed to attach overnight. They were
withdrawn from endogenous steroids essentially as described
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above except that for the first 3 days the medium was
changed twice daily and the cells were not washed with PBS.
On the fifth day, the indicated drug or solvent alone were
added to the culture medium and thereafter medium was
changed daily.
For the measurement of cathepsin D synthesis, cells were
plated into 8-mm wells, withdrawn from the endogenous
steroids present in the maintenance medium and treated with
various concentrations of oestradiol and tamoxifen as
described for the analysis of the regulated RNAs. Cells were
labelled with 35S-methionine (200pCiml-1) for 1 or 6h as
described by Westley & Rochefort (1980) and cell extracts
prepared for immunoprecipitation according to Buetti &
Diggelmann (1981).
Preparation and analysis of RNA
Total RNA was prepared, denatured, electrophoresed
through denaturing agarose gels and transferred to
nitrocellulose or nylon membranes as described by May &
Westley (1987). 32P-labelled probes were synthesised by
transcription from cDNA subcloned into pGEM and
Bluescript vectors. Hybridisation to the immobilised RNA
was at 65°C in a solution containing 50% formamide
(Melton et al., 1984). The amount of radiolabelled probe
hybridised was quantified by densitometric scanning of the
autoradiographs.
DNA measurement
The cells were lysed in a solution of triton X-100 and
ammonia and the DNA measured using bisbenzimidazole
(Hoechst 33258) on a Kontron SFM 25 spectrofluorometer
(Downs & Wilfinger, 1983). The DNA content of one of the
wells treated with oestradiol for 9 days was taken as the
100% value for each experiment. Triplicate wells were
analysed for each time point.
Immunoprecipitation
3IS-labelled cellular proteins (200,000c.p.m.) were
immunoprecipitated with mono-specific polyclonal rabbit
antisera against human cathepsin D (Reid et al., 1986) using
protein-A sepharose. Immunoprecipitates were analysed on
12% polyacrylamide gels which were processed for
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fluorography and exposed to prefogged X-ray film at
-70'C. The incorporation of 35S-methionine into cathepsin
D was measured by densitometric scanning of the X-ray
films (Laskey & Mills, 1975).
Results
Oestrogen-dependent growth of MCF-7 cells
To optimise the conditions for maximal oestrogenic
stimulation of MCF-7 cell growth, several MCF-7 sublines
were tested. Although the growth of all sublines was
stimulated, the subline chosen for this study showed the
greatest stimulation (usually more than 10-fold over a 9-day
period) and did not detach even during periods of prolonged
withdrawal in phenol red-free medium.
The effect of oestrogen on the proliferation of these MCF-
7 cells is shown in Figure 1. There was complete cessation of
the growth of cells cultured continuously in the withdrawal
medium alone. The stimulation of the growth by oestradiol
was dose dependent. A small increase was detected in the
presence of 10-12M oestradiol and growth was maximal
after the addition of 10-10M oestradiol to the culture
medium. In this experiment, there was an increase of
approximately 60-fold in the DNA recovered from cells
grown for 9 days in the presence of oestrogen. The dose-
response curve of the growth stimulation by oestradiol after
9 days of culture in its presence indicates that the increase is
half-maximal in 5 x 10 12M oestradiol.
Regulation of cell growth and oestrogen-regulated RNAs by
tamoxifen
The ability of tamoxifen to influence the growth of MCF-7
cells in both the absence and presence of oestradiol was
tested as described in Materials and methods. As in the
experiment described above, there was complete cessation of
the growth of cells cultured in the withdrawal medium alone
whereas the addition of 10-8M oestradiol to the culture
medium promoted cell proliferation (Figure 2a). Tamoxifen
at 1V-8M had no effect on the proliferation of the MCF-7
cells. However, 10-6 and 10-7M tamoxifen stimulated cell
growth.
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Figure 1 Stimulation of MCF-7 cell proliferation by oestradiol. a, Cells were withdrawn and then treated with various
concentrations of oestradiol for the indicated lengths of time. The amount of DNA per well is expressed as a fraction of the DNA
in a well of cells treated with 10 -7 M oestradiol. The mean (0) and the standard error from the mean (bars) of at least three
determinations are shown. b, The amount of DNA in cells grown for nine days in the presence of the indicated concentration of
oestradiol is expressed as a percentage of the maximum level.
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Figure 2 Effect of tamoxifen on MCF-7 cells. a, Cells were withdrawn for 5 days and then cultured in the withdrawal medium
alone (0 0), or containing 10-8 M oestradiol (0-0), or 10-8, 10-7 or 10-6 M tamoxifen (0 0) for the indicated lengths of
time. b, Cells were withdrawn for 5 days and then cultured in the withdrawal medium alone (0 0) or containing 2 x 101 -M
oestradiol alone (0 0) or plus 10-7, 10-6 or 10 - M tamoxifen for the indicated length of time (0 0). The concentration of
DNA in each well is expressed as a fraction of the amount in one of the oestradiol treated wells for each experiment. The values
shown are the mean of three determinations plus or minus the standard error of the mean. c, MCF-7 cells were withdrawn for 7
days and then cultured for 3 days in the indicated concentration of tamoxifen alone (0-0) or in the presence (0-0) of
2 x 101 -M oestradiol. Total RNA was prepared, separated by gel electrophoresis, and transferred to a membrane support. The
filters were hybridised with radiolabelled RNA probes and the amount hybridised was measured by scanning autoradiographs
obtained using preflashed X-ray film exposed at - 70°C. The amount of cDNA hybridised is plotted as a percentage of the
amount in oestrogen-treated cells for each plasmid. The dashed lines indicate the levels of the RNAs in cells grown continuously
in the withdrawal medium.
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Cells grown simultaneously in the presence of 2 x 10-1°M
oestradiol and 10-7 M tamoxifen grew at the same rate as
cells grown in the presence of 2 x10-10M oestradiol alone
(Figure 2b). Tamoxifen at 10-6M inhibited the oestrogen-
induced cell proliferation by approximately 20%. The effect
of 2 x 10-1 M oestradiol on MCF-7 cell growth was almost
completely inhibited by 1-5 M tamoxifen.
The effect of tamoxifen on the levels of four oestrogen-
induced RNAs, pNR-1, pNR-2, pNR-25 and cathepsin D,
was tested in the MCF-7 cell subline used in the growth
experiments (Figure 2c). In these MCF-7 cells, tamoxifen
increased the level of the pNR-1 RNA to 200% of the level
induced by oestradiol. The induction was dose-dependent
and was half-maximal at approximately 2 x 10-8 M
tamoxifen. In the presence of oestradiol, tamoxifen also
induced pNR-1 RNA levels above the maximal level induced
by oestradiol to the level obtained in cells treated with
tamoxifen alone. The additional increase was half-maximal
in the presence of 4 x 10-7 M tamoxifen.
Tamoxifen was much less oestrogenic for the induction of
the pNR-2 RNA. Tamoxifen alone induced the pNR-2 RNA
to about 30% of the level present in oestradiol treated cells.
It inhibited the induction of the pNR-2 RNA by 2 x 10 1- M
oestradiol, to the levels found in cells treated with tamoxifen
alone. The inhibition was half-maximal in the presence of
5 x 10-6 M tamoxifen.
The pNR-25 RNA was induced by 10-6M tamoxifen, to
approximately 15% of the level in oestrogen-treated cells.
The induction was half-maximal in the presence of
5 x 10-8 M tamoxifen. The induction by oestradiol of pNR-
25 RNA levels was inhibited by tamoxifen; half-maximal
inhibition was achieved by 4 x 10-6M tamoxifen.
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The induction of cathepsin D RNA by tamoxifen was
half-maximal at 5x 10-8M. In the presence of 1O-6M
tamoxifen, cathepsin D RNA levels were the same as in
oestrogen-treated cells. In the presence of 2 x 10-10M
oestradiol, the effect of increasing concentrations of
tamoxifen on cathepsin D RNA levels was dramatic (Figures
2c and 3). Maximal cathepsin D RNA levels of eight times
the level in cells treated with oestradiol alone were induced
by simultaneous treatment with 2x10 1-M oestradiol and
between 10-6 and 5 x10-6M tamoxifen. Above 5 x 10-6M
tamoxifen, cathepsin D RNA levels were lower but remained
above the levels in cells treated with 2x1010M oestradiol
alone.
Regulation of cell growth and oestrogen-induced
RNAs by N-desmethyltamoxifen
The effects of N-desmethyltamoxifen on the proliferation of
MCF-7 cells are shown in Figure 4a. While it had no effect
at 10-5M, N-desmethyltamoxifen stimulated the
proliferation at both 10-6 and 10-7M. The increase in cell
numbers induced by 10- M N-desmethyltamoxifen was 24%
of the increase induced by oestradiol. Neither 10-7 nor
10-6M N-desmethyltamoxifen had any effect on the cell
proliferation induced by 2x 10 1-M oestradiol whereas
10- IM N-desmethyltamoxifen almost completely inhibited
the effect of oestradiol (Figure 4b).
The levels of the four oestrogen-regulated RNAs in cells
grown in the presence of different concentrations of N-
desmethyltamoxifen are shown in Figure 4c. The induction
of pNR-1 RNA levels by N-desmethyltamoxifen both alone
and in the presence of oestradiol was similar to the induction
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Figure 3 Induction of cathepsin D RNA levels by tamoxifen, N-desmethyltamoxifen, 4-hydroxytamoxifen and 3-
hydroxytamoxifen in the presence of oestradiol. Withdrawn MCF-7 cells were cultured for 3 days in withdrawal medium
containing 2 x 10-1- M oestradiol together with the indicated concentration of tamoxifen (0-0), N-desmethyltamoxifen (0 0),
4-hydroxytamoxifen (O *) or 3-hydroxytamoxifen (OI-0). Cathepsin D RNA levels were measured as described in Materials
and methods and are expressed as a percentage of the levels in oestrogen treated cells.ANTI-OESTROGENS AND MCF-7 CELLS 731
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Figure 4 Effect of N-desmethyltamoxifen in MCF-7 cells. a and b, Withdrawn cells were cultured in the withdrawal medium
alone (0 0) or containing I10 M (a) or 2 x 10-1 M (b) oestradiol (0-0), or different concentrations of N-desmethyltamoxifen
(@-@) in the absence (a) or presence (b) of 2 x 101 -M oestradiol for the indicated lengths of time. The data are expressed as
described in the legend to Figure 2. c, MCF-7 cells were withdrawn and then cultured in the indicated concentrations of N-
desmethyltamoxifen in the presence (@-0) or absence of 2 x 10- I0 M oestradiol (0-0). The levels of the pNR-1, pNR-2, pNR-
25 and cathepsin D RNAs were measured as described in the legend to Figure 2c.
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by tamoxifen. Induction by N-desmethyltamoxifen alone was
half-maximal at about 2 x 10- 8M and the additional
induction in the presence of oestradiol was half-maximal at
about 4 x 10-6M N-desmethyltamoxifen.
On its own, N-desmethyltamoxifen had little effect on
pNR-2 RNA levels, but inhibited the oestrogen-induction
with half-maximal inhibition at around 10 5M. N-
Desmethyltamoxifen did, however, induce the pNR-25 RNA
levels to approximately the same extent as tamoxifen.
Maximal induction was attained in the presence of 1O- M.
N-Desmethyltamoxifen completely inhibited the induction of
the pNR-25 RNA by oestradiol at 1O-5M. The inhibition
was half-maximal at approximately 2 x 10-6M
N-desmethyltamoxifen.
N-Desmethyltamoxifen was less oestrogenic than
tamoxifen for the induction of cathepsin D RNA. At 10-7M
it increased cathepsin D RNA levels to approximately 40%
of those in oestrogen-treated cells. In the presence of
2 x 10 10M oestradiol, there was an additive effect similar to
but less dramatic than that observed with tamoxifen (Figures
3 and 4c). Maximum cathepsin D levels of 3.3 times the level
in oestradiol treated cells were induced by 3 x 0-6M N-
desmethyltamoxifen and 2 x 10-IOM oestradiol.
Regulation of cell growth and oestrogen-induced
RNAs by 4-hydroxytamoxifen
4-Hydroxytamoxifen stimulated cell proliferation at 10-9M
but had no effect at the other concentrations tested, apart
from 1O-5M, which was cytotoxic (Figure 5a). At 10-5 and
10-6M it completely inhibited the stimulation of cell
proliferation induced by oestradiol. In the presence of
10-7 M 4-hydroxytamoxifen and 2 x 101 -M oestradiol, cells
grew at the same rate as cells cultured in 2 x10-10M
oestradiol alone.
The induction of the pNR-1 RNA by 4-hydroxytamoxifen
was, however, similar to that obtained with tamoxifen and
N-desmethyltamoxifen. The induction by 4-
hydroxytamoxifen alone was half-maximal at about
3 x10 1-M and the stimulation above the level induced by
oestradiol in the presence of both drugs was half-maximal at
around 4 x 10-7 M 4-hydroxytamoxifen. 4-Hydroxytamoxifen
alone had no effect on the levels of the pNR-2 and pNR-25
RNAs. At a concentration of 3 x 10-7M, 4-
hydroxytamoxifen completely inhibited the induction by
oestradiol of these two RNAs. The induction of the
cathepsin D RNA by 4-hydroxytamoxifen was half-maximal
at 4 x 10-10M and attained the levels present in cells
maximally stimulated by oestradiol. The dose-response curve
for the induction of cathepsin D RNA levels by 4-
hydroxytamoxifen in the presence of oestradiol was bell-
shaped with a maximum at 2 x 10-7 M (Figures 3 and Sc). At
this concentration, the cathepsin D RNA concentration was
approximately 5 times that in oestradiol-treated cells.
Regulation of cell growth and oestrogen-induced
RNAs by 3-hydroxytamoxifen
3-Hydroxytamoxifen stimulated the proliferation of MCF-7
cells at 10-8M but not at 10- 5 or 10-11M (Figure 6a). After
9 days' treatment, the increase induced by 3-
hydroxytamoxifen was 14% of the induction by oestradiol.
The cell proliferation induced by 2 x 10-10M oestradiol was
not affected by 10-9M 3-hydroxytamoxifen, but was
substantially reduced by 10-6M and was completely
inhibited by 1O-5M 3-hydroxytamoxifen (Figure 6b).
The effects of 3-hydroxytamoxifen on the levels of the
oestrogen-induced RNAs are shown in Figure 6c. The pNR-1
RNA was induced to 150% of the level induced by
oestradiol; with half-maximal induction in the presence of
- 1.5 x 10-9M 3-hydroxytamoxifen. In the presence of
oestradiol, 3-hydroxytamoxifen induced the pNR-1 RNA
levels above the level induced by oestradiol to the level
obtained with 3-hydroxytamoxifen alone.
The pNR-2 and pNR-25 RNA levels were both induced
by 10-8 M 3-hydroxytamoxifen to 10% and 20%,
respectively, of the levels induced by oestradiol. The
induction of both RNAs by oestradiol was completely
inhibited by this antioestrogen. Cathepsin D RNA was
induced to the levels found in oestradiol-treated cells by
10- 6M 3-hydroxytamoxifen. The induction was half-maximal
in the presence of 5 x 10-8M 3-hydroxytamoxifen. The levels
of cathepsin D RNA in cells treated simultaneously with
2x10 10M oestradiol and different concentrations of 3-
hydroxytamoxifen gave a bell-shaped curve with a maximum
at 3 x10- 7M 3-hydroxytamoxifen (Figures 3 and 6c).
Regulation of cell growth and oestrogen-induced
RNAs by metabolite E
The effects of metabolite E on cell growth are shown in
Figure 7a. In the presence of 10-9M metabolite E, MCF-7
cells grew at 70% of the rate induced by 10-8M oestradiol.
Metabolite E at 10-7 M was as effective as oestradiol at
stimulating the growth of these MCF-7 cells. Cells cultured
in 2 x I0-IM oestradiol alone or in the presence of 10-,
10-6 or 10-7M metabolite E grew at the same rate.
Metabolite E was also as effective as oestradiol for the
induction of the four oestrogen-regulated RNAs. Half-
maximal induction was attained at 4 x10-10M for pNR-1,
8 x10-9M for the pNR-2, 1.5 x10-9M for pNR-25, and
1.5 x10-9M for cathepsin D. The RNA levels induced by
metabolite E were the same as those found in oestradiol-
treated cells.
Effects of oestrogen and tamoxifen on cathepsin D synthesis
To determine whether the increased cathepsin D RNA levels
that are induced by combined oestradiol and tamoxifen
treatment result in increased synthesis of cathepsin D, newly
synthesised proteins were labelled with 35S-methionine for
1 h. Incorporation into cathepsin D was then measured using
immunoprecipitation as described in the Materials and
methods. A single band of approximately 46 kDa was seen,
which corresponds to pro-cathepsin D. Overall, the effects of
oestradiol and tamoxifen on pro-cathepsin D synthesis were
very similar to the effects on its RNA (Figure 8). Labelling
of pro-cathepsin D was increased 10-fold by oestradiol
(2 x 10 1-M). Tamoxifen alone increased pro-cathepsin D
synthesis at concentrations above 10-8M. Maximal levels
were obtained at 3 x10-7M and these were similar to the
oestradiol stimulated levels.
The synthesis of pro-cathepsin D was at the oestrogen
stimulated level in the presence of oestradiol and tamoxifen
together up to a concentration of 3 x 10-7 M tamoxifen. At
higher concentrations of tamoxifen (10-6 to 5 x10-6M)
synthesis of pro-cathepsin D was 3.2-fold higher than in
oestrogen stimulated cells. This dropped to 1.6-fold in the
presence of 10-M tamoxifen and 2 x10-0M oestradiol.
The secretion of cathepsin D from MCF-7 cells (treated
with the same concentrations of oestradiol and tamoxifen as
in the experiments described above) was measured following
a 6-h labelling with 35S-methionine. The amount of cathep-
sin D secreted into the medium closely mirrored its synthesis
(data not shown).
Discussion
The growth of the MCF-7 cells described in this report was
extremely sensitive to oestrogen. The growth stimulation was
dose dependent with near maximal proliferation in the
presence of 10-10M oestradiol. The effects of tamoxifen and
its derivatives varied significantly, although all five stimu-
lated cell proliferation. 4-Hydroxytamoxifen alone stimulated
cell proliferation only slightly at a single concentration
(10-9M) and was cytotoxic at 10-5M. Tamoxifen, N-
desmethyltamoxifen and 3-hydroxytamoxifen all stimulated
cell proliferation to a greater extent. The stimulation was
dose-dependent, following a bell-shaped curve, with no effect
in the presence of 10- M. No cytotoxic effects of high
concentrations of these three anti-oestrogens were observedANTI-OESTROGENS AND MCF-7 CELLS 733
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Figure 5 Effect of 4-hydroxytamoxifen in MCF-7 cells. a and b, Withdrawn cells were cultured in the withdrawal medium alone
(0 0), or containing 10- 8 M (a) or 2 x 10- 10 M (b) oestradiol (0 0), or different concentrations of4-hydroxytamoxifen (0 0)
in the absence (a) or presence (b) of 2 x 10- 10 M oestradiol for the indicated lengths of time. The data are expressed as described in
the legend to Figure 2. c, MCF-7 cells were withdrawn and then cultured in the indicated concentrations of 4-hydroxytamoxifen in
the presence (0 0) or absence of 2 x 10-10M oestradiol (0 0). The levels of the pNR-l, pNR-2, pNR-25 and cathepsin D
RNAs were measured as described in the legend to Figure 2c.
a
z O.E
0
3
0
0
pNR-2
0
pNR-25
200-
100-
a)
LU
0
200-
100-
-11 -10
- I
v734 M.D. JOHNSON et al.
3-Hydroxytamoxifen
01)
a)
Z 05
0
- 8
-11
- 5
3 6 9
Days of treatment
-9
- 6
-5
6
a)
w
04 LL
-80
-11 -10 -9 -8 -7 -6 -5 11 -10 -9 -8 -7 -6 -5
Logl0 3-hydroxytamoxifen concentration (M)
Figure 6 Effect of 3-hydroxytamoxifen in MCF-7 cells. a and b, Withdrawn cells were cultured in the withdrawal medium alone
(0 0), orcontaining 10-8 M (a) or 2 x 10 10M (b) oestradiol (0-0), or different concentrations of3-hydroxytamoxifen (0 0)
in the absence (a) or presence (b) of2 x 10 10 M oestradiol for the indicated lengths of time. The data are expressed as described in
the legend to Figure 2. c, MCF-7 cells were withdrawn and then cultured in the indicated concentrations of 3-hydroxytamoxifen in
the presence (0-0) or absence (0-0) of 2 x 10-10 M oestradiol. The levels of the pNR-1, pNR-2 pNR-25 and cathepsin D
RNAs were measured as described in the legend to Figure 2c.
IANTI-OESTROGENS AND MCF-7 CELLS 735
Metabolite E
-5
- 6
-7
3 6 9
Time of treatment (Days)
-11 -10 -9 -8 -7 -6 -5 -11 -10 -9 -8 -7 -6 -5
Log10 Metabolite E concentration (M)
Figure 7 Effect of metabolite E in MCF-7 cells. a and b, Withdrawn cells were cultured in the withdrawal medium alone
(0 0). or containing 10 -8 M (a) or 2 x 1-I M (b) oestradiol (0-0), or different concentrations of metabolite E (0-0) in
the absence (a) or presence (b) of 2 x 1O-I0M oestradiol for the indicated lengths of time. The data are expressed as described in
the legend to Figure 2. c, MCF-7 cells were withdrawn and then cultured in the indicated concentrations of metabolite E (0 0).
The levels of the pNR-l, pNR-2, pNR-25 and cathepsin D RNAs were measured as described in the legend to Figure 2c.
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Figure 8 Effect of oestradiol and tamoxifen on the synthesis of
cathepsin D. MCF-7 were plated into 8 mm diameter wells,
withdrawn for 5 days and then cultured in withdrawal medium
alone (---), 10-8 M oestradiol (---), the indicated concent-
ration of tamoxifen alone (0-0) or 2 x 10-10M oestradiol
together with the indicated concentration of tamoxifen (0-0).
Cathepsin D synthesis was determined as described in Materials
and methods and is expressed as a percentage of that in
oestrogen-stimulated cells.
and all three compounds inhibited the oestrogen-induced
proliferation in a dose-dependent manner.
The relative binding affinities of the four compounds for
the oestrogen receptor in MCF-7 cells or rat uterus (Coezy
et al., 1982; Furr & Jordan, 1984; Roos et al., 1983) agree
well with the doses at which they inhibit oestrogen-induced
growth. For instance at 10-6M, 4-hydroxytamoxifen comple-
tely blocked the effect of oestrogen, 3-hydroxytamoxifen
reduced it by 75%, tamoxifen by 25%, and N-
desmethyltamoxifen was ineffective. In contrast, the degree
to which they acted as oestrogens was not related to their
affinity for the oestrogen receptor.
Berthois et al. (1986) reported that tamoxifen and 4-
hydroxytamoxifen stimulate cell growth in phenol red-free
medium at concentrations of 10-10M and 10-8M respec-
tively. In a subsequent study (Katzenellenbogen et al., 1987),
a more extended range of concentrations was used and
growth stimulation was observed at 10-10 and 10-9M
hydroxytamoxifen and at 10-10 to 10-7M tamoxifen. Our
data are therefore in broad agreement with these two studies
except that we did not observe stimulation at 10-8 M
tamoxifen.
The growth stimulation of the MCF-7 cells by metabolite
E was near maximal at 10-9 M. This is a lower concentration
than would have been predicted from its relative binding
affinity for the rat uterine oestrogen receptor (Furr &
Jordan, 1984) and suggests that the affinity of metabolite E
for the human oestrogen receptor may be higher than
reported. Different concentrations of metabolite E had no
effect on the cell proliferation induced by a maximally
stimulating concentration of oestradiol (2 x O- 1OM). The
complete absence of any additive effect of these two com-
pounds on cell growth indicates that they act by the same
mechanism.
The stimulatory effects of tamoxifen and its metabolites
on the growth of breast cancer cells has clear implications
for the treatment of advanced carcinoma of the breast with
tamoxifen. The major metabolites of tamoxifen detected in
patients are N-desmethyltamoxifen and 4-hydroxytamoxi-
fen (Robinson & Jordan, 1988). The mean tumour con-
centrations in women on tamoxifen (40 mg daily) are
25.1 ngmg protein-1 for tamoxifen, 52 ngmgprotein-
for N-desmethyltamoxifen, and 0.53 ngmgprotein-
for 4-hydroxytamoxifen (Daniel et al., 1981).
At these concentrations, which are in approximately
inverse proportion to the relative binding affinities of the
three anti-oestrogens for the oestrogen receptor, they could
all affect the growth of oestrogen-responsive tumour cells. In
the absence of endogenous oestrogens, the relative concent-
rations of these three anti-oestrogens would determine the
growth response of the tumour cells. It is also possible that
the tumour flare observed in some patients occurs during the
transitory period in which tamoxifen or N-
desmethyltamoxifen are present at higher concentrations
before the accumulation of significant concentrations of 4-
hydroxytamoxifen (Milano et al., 1987).
In the presence of oestrogens, the growth of all oestrogen-
responsive tumour cells would be inhibited by the three anti-
oestrogens. Maximal growth inhibition would be dependent
on the concentrations attained in the tumour cells.
Metabolite E was originally identified in bile but has been
found as a minor metabolite in human plasma (Murphy et
al., 1987). It has not been detected in breast tumour cells. In
the absence of any data on the intra-tumour concentrations
of metabolite E, it is not possible to assess whether it has a
significant oestrogenic effect in tumours of patients receiving
tamoxifen. Because it is biologically active at a 100-fold
lower concentration than tamoxifen, there may be biologi-
cally active concentrations in tumours that have escaped
detection due to their low levels relative to tamoxifen and
the major metabolites. Whatever the situation in vivo, these
experiments establish the principle that in vivo metabolites of
anti-oestrogens can be full oestrogens for the growth stimu-
lation of human breast cancer cells.
The effects of the five anti-oestrogens on the levels of the
four oestrogen-regulated RNAs also varied. As with cell
growth, metabolite E was a full oestrogen for the induction
of all four RNAs. The oestrogenicity of the other anti-
oestrogens for the induction of the RNAs appeared specific
for each RNA. All four induced the pNR-1 RNA above the
level induced by oestrogen. Cathepsin D RNA was induced
to the same level by oestrogen and three of the four anti-
oestrogens. The pNR-2 and pNR-25 RNA levels were less
affected by the anti-oestrogens. Although the maximal effect
of the drugs was not related to their affinity for the
oestrogen receptor, the concentration at which they were
active was (see Table I for summary).
These results are in broad agreement with, but substan-
tially extend, a previous study in which the effects of
tamoxifen and 4-hydroxytamoxifen on pNR-l and pNR-2
RNA levels were measured (May & Westley, 1987). In that
study, tamoxifen and 4-hydroxytamoxifen induced the pNR-
1 RNA levels to 80% of the level in oestradiol-treated cells.
The induction by tamoxifen in the present study was even
greater (2-fold) than that of oestradiol. Two different sub-
lines of MCF-7 cells were used in the two studies. The
subline used in this study was chosen because it showed a
better proliferative response to oestradiol. These results
suggest that it is also more responsive to tamoxifen and its
metabolites.
Tamoxifen, N-desmethyltamoxifen, 4-hydroxytamoxifen
and 3-hydroxytamoxifen all inhibited the induction of the
pNR-2 and pNR-25 RNAs by oestradiol. The relative
concentrations required for half-maximal inhibition were
inversely proportional to their relative affinities for the
oestrogen receptor. Interestingly in the presence of oestrogen,
although tamoxifen and its derivatives induced the pNR-1
RNA levels to the same level as in the absence of oestrogen,
a higher concentration of the drug was required. It appears
k
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Table I Summary of effects of anti-oestrogens on
oestrogen-regulated RNAs
cell growth and the four
Cathepsin
Growth pNR-1 pNR-2 pNR-25 D
Tamoxifen
Induction:
% of oestradiol 20 200 30 15 100
Concentration
(log molar) -7 -7 -6 -7 -7
Inhibition:
concentration No No
(log molar) -5 inhibition -5 -5 inhibition
N-desmethyltamoxifen
Induction: No
%of oestradiol 25 200 induction 18 30
Concentration
(log molar) -7 -7 -7 -7
Inhibition:
concentration No No
(log molar) -5 inhibition -5 -5 inhibition
4-hydroxytamoxifen
Induction: No No
% of oestradiol 8 200 induction induction 100
Concentration
(log molar) -9 -9 -9
Inhibition:
concentration: No No
(log molar) -6 inhibition -6 -6 inhibition
3-hydroxytamoxifen
Induction:
% of oestradiol 13 150 22 10 100
Concentration
(log molar) -8 -8 -9 -8 -7
Inhibition:
concentration No No
(log molar) -5 inhibition -5 -5 inhibition
Metabolite E
% of oestradiol 100 100 100 100 100
Concentration
(log molar) -7 -8 -7 -7 -8
For each anti-oestrogen, the maximum induction (expressed as a percentage of the
oestrogen induced level) is shown together with the concentration required for
maximal induction. The concentration required to inhibit the induction by 0.2nM
oestradiol is also given.
that oestrogen is acting as a tamoxifen antagonist for the
induction of the pNR-l RNA.
The effect of tamoxifen and its derivatives on the levels of
cathepsin D RNA in the presence of oestrogen was more
bizarre (Figure 3). The induction followed a bell-shaped
dose-response curve. The stimulation was greatest for
tamoxifen and least marked for N-desmethyltamoxifen. The
relative concentrations of the four drugs that gave maximum
stimulation agreed with their relative affinities for the oestro-
gen receptor.
As these effects were so dramatic, cathepsin D synthesis
was measured in cells cultured under the same conditions as
in the RNA experiments. Similar dose-response curves were
obtained and cathepsin D synthesis was more than 3-fold
higher in cells treated with oestradiol and 1-5 x 1o-6 M tamoxi-
fen than in cells treated with oestradiol alone. This shows
that the alterations in cathepsin D mRNA levels effected by
small changes in the relative concentrations of tamoxifen and
oestradiol can cause a large difference in the level of
cathepsin D synthesis.
The mechanisms involved in this synergistic effect are
currently unclear. At low concentrations of the anti-
oestrogen, most of the receptor would be complexed with
oestradiol whereas at higher concentrations of the anti-
oestrogens, some oestrogen receptors would be complexed
with oestradiol and some with the anti-oestrogen. In this
situation, there is a greater induction of the cathepsin D
gene than in the presence of oestradiol alone. At high
concentrations of the anti-oestrogens, all of the oestrogen
receptor molecules will be complexed with anti-oestrogen
and the expression of the cathepsin D gene is as found in
cells treated with the anti-oestrogen alone.
Steroids are thought to regulate gene expression by an
interaction of the receptor complex with regulatory DNA
sequences and it has been suggested that the oestrogen
receptor binds to oestrogen response elements as a dimer
(Kumar & Chambon, 1988). It is therefore possible that an
oestrogen receptor dimer complexed with one oestradiol and
one anti-oestrogen molecule is interpreted by the cathepsin D
response element as being more oestrogenic than a receptor
dimer complexed with two oestradiol or two anti-oestrogen
molecules.
The combined effect of tamoxifen and oestradiol on the
induction of cathepsin D RNA could have clinical impli-
cations. Although the biological role of cathepsin D in
breast tumours is not known, it has been proposed to be
involved in tumour dissemination as it can be secreted from
breast tumour cells (Westley & Rochefort, 1980) and can
degrade extracellular matrix (Briozzo et al., 1988). The
present observations suggest that tamoxifen treatment might
enhance any tumour dissemination mediated by cathepsin D.
However, cathepsin D is also thought to be involved in738 M.D. JOHNSON et al.
tissue involution and remodelling; and in processes such as
post-partum involution of the uterus, cathepsin D levels are
under some degree of hormonal control (Afting et al., 1979).
Cathepsin D may therefore play an active role in tumour
regression and the dramatic elevation of cathepsin D by
tamoxifen in the presence of oestradiol might facilitate this
process. This model would predict that high levels of cathep-
sin D in primary tumours should be associated with a good
prognosis. In this context, a recent immunohistochemical
study has shown that high levels of cathepsin D in breast
cancer cells is indicative of a good prognosis in oestrogen
receptor positive tumours (J.A. Henry, personal communi-
cation). It will be interesting to determine how patients who
express high tumour levels of cathepsin D respond to
tamoxifen therapy.
A previous study did not detect a synergistic effect
between oestradiol and tamoxifen on the secretion of cathep-
sin D from MCF-7 cells (Westley & Rochefort, 1980). The
discrepancy between the two studies may be accounted for
by differences in experimental protocols, such as the use of
phenol red-free medium or the more detailed dose-response
curves obtained in the present study. Alternatively, the two
MCF-7 sublines used may respond differently. This is cur-
rently being investigated.
Tamoxifen and its metabolites have extremely variable
effects on cell proliferation and the levels of oestrogen-
inducible RNAs in MCF-7 cells. Comparison of the effects
of each compound on cell growth and RNA expression
should identify those RNAs whose levels are correlated with
cell growth. Such an RNA might be valuable as a marker
for predicting and/or monitoring responses to endocrine
therapy and might itself be implicated in the growth
response.
The regulation of the pNR-2 and pNR-25 RNAs are most
closely allied to cell growth (Table I). The growth stimula-
tion and regulation of the two RNAs by tamoxifen, 3-
hydroxytamoxifen and metabolite E is similar and occurs at
approximately the same concentration for each anti-
oestrogen. The concentrations at which all four anti-
oestrogens inhibit the induction by oestradiol of cell growth
and the levels of the pNR-2 and pNR-25 RNAs also agree
well. However, although N-desmethyltamoxifen does not
affect the levels of the pNR-2 RNA, it does stimulate MCF-
7 cell proliferation and increase the levels of the pNR-25
RNA. We are currently evaluating these two RNAs as
predictive markers of response to anti-oestrogen therapy.
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